December 6, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the separately managed healthcare business of Siemens AG presented itself for the first time under its new brand name, Siemens Healthineers. The company featured several new releases, including a new, expanded version of xSPECT Quant, an established single-photon emission computed tomography (SPECT) quantification technology.
The expanded version of xSPECT Quant enables users of the company’s Symbia Intevo SPECT/CT system to perform automated, accurate and reproducible quantification of not just Technetium-99m – the most common isotope in SPECT imaging – but also, for the first time, Iodine-123, Lutetium-177 and Indium-111. This expansion of quantifiable isotopes extends the use of advanced SPECT quantification from general nuclear medicine and bone studies to indications including neurological disorders, neuroendocrine tumors, neuroblastoma and prostate cancer.
xSPECT Quant is the first and only technology, according to the company, to use a 3 percent National Institute of Standards and Technology (NIST) traceable precision source, enabling standardization of uptake values for reliable disease detection and evaluation of therapy response across imaging centers, cameras and dose calibrators. And the technology offers clinicians higher reproducibility than traditional quantification methods. The absolute quantification capabilities of xSPECT Quant also can facilitate theranostics, an emerging approach employing radioactive isotopes that emit energies to not only image but also enable the physician to treat the patient’s disease.
For more information: www.siemens.com/healthineers
July 30, 2024 
